Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events

The purpose of this study is to monitor physiological and molecular changes during and following CAR-T cancer cell therapy, towards improved management of adverse events including Cytokine Release Syndrome and neurotoxicity. Our study aims are to improved early detection and precise management of adverse events for patients receiving Chimeric antigen receptor T- cell (CAR-T): To assess the feasibility, including accuracy, usability, and usefulness of wearable sensors in CAR-T patients. To generate comprehensive multiomic profile analysis following CAR-T therapy. To perform integrated analysis of wearables sensor data, omics data, and symptom/clinical data.

Blood microsamples will be collected at start of conditioning chemotherapy, daily while in the hospital, and after leaving the hospital and outpatient appointments.

Safety will be measured by skin irritation, rash. Will be assessed using CTCAE criteria version 5 to evaluate by any adverse event definitely, probably or possibly related to the wearable devices

Microsampling will be measured by process such as minor bruising, bleeding, or infection. Will be assessed using CTCAE criteria version 5 to evaluate by any adverse event definitely, probably or possibly related to the wearable devices

Inclusion Criteria: Participant must be in the process of undergoing cancer cell therapy at Stanford University. Adults > 18 years Any cell target may be used. (e.g. CD19, CD22, Bispecific CD19/22, Bispecific CD19/20, etc.) English speaking Assessed ability for caregiver/patient to use wearable devices and independently perform blood microsample collection Exclusion Criteria: In the investigator's judgment, the subject is unlikely to comply with all protocolrequired study visits or procedures.